Modifiable risk factors and major cardiac events among adult survivors of childhood cancer.

By G. Armstrong, K. Oeffinger, Yan Chen, T. Kawashima, Y. Yasui, W. Leisenring, M. Stovall, E. Chow, C. Sklar, D. Mulrooney and 5 more. Journal of Clinical Oncology, 2013

629 citations recorded by the source corpus.

Subfields: Cardiology and Cardiovascular Medicine, Oncology, Pediatrics, Perinatology and Child Health

View Paper: https://www.semanticscholar.org/paper/7b6801eef868f6a69abaa12df3aa1c3c66262709

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cardiology and Cardiovascular Medicine

In Oncology

In Pediatrics, Perinatology and Child Health

Citations in the corpus

Prevention of anthracycline-induced cardiotoxicity: challenges and opportunities. (2014, background): “This study also reported that cardiovascular risk factors, such as hypertension, diabetes, dyslipidemia, and obesity, are significantly higher in cancer survivors than in the healthy population (13).”
2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines (2016, background): “tion and structure, or may be due to accelerated development of CVD, especially in the presence of traditional cardiovascular risk factors.(4) Although the field of cardio-oncology has received increasing attention in recent years, many aspects of both radiation-induced and cancer drug– induced CVD ”
Anthracycline Chemotherapy and Cardiotoxicity (2017, background): “The predictors for cardiovascular outcomes after cancer survival include age at time of diagnosis, female gender in childhood cancer survivors, chest radiotherapy, time since cancer treatment [13] and anthracycline dosage [73].”
Shared Risk Factors in Cardiovascular Disease and Cancer (2016, background): “In multivariable models, hypertension alone significantly increased risk for all major cardiac events among survivors exposed to both chest-directed radiotherapy and anthracyclines.(111)”
2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). (2016, background): “tion and structure, or may be due to accelerated development of CVD, especially in the presence of traditional cardiovascular risk factors.(4) Although the field of cardio-oncology has received increasing attention in recent years, many aspects of both radiation-induced and cancer drug– induced CVD ”
Cancer treatment and survivorship statistics, 2016 (2016, background): “Recent declines in late morbidity and mortality among childhood cancer survivors are due in part to reduced use of certain treatments, such as cranial radiation for ALL and abdominal radiation for Wilms tumor.(45) However, even many newer, less toxic therapies increase the risk of serious health con”
Childhood and adolescent cancer statistics, 2014 (2014, background): “Modifiable cardiovascular risk factors, such as hypertension, can potentiate the risk of major cardiac events and both behavioral and medical interventions can potentially reduce these risks.(136) Research to define optimal intervention strategies and well-integrated survivorship care models are bot”